First Quarter of Fiscal 2014
Updates Related to R&D Activities

Tsudoi Miyoshi
Senior Vice President
Head of CMSO Office

August 1, 2014

Takeda Pharmaceutical Company Limited

R&D Pipeline Stage-ups (since May 8, 2014)

			Ph-1	Ph-2	Ph-3	Filing	Approval
ENTYVIO™ (vedolizumab)	Ulcerative colitis	US/EU					✓
ENTYVIO™ (vedolizumab)	Crohn's disease	US/EU					✓
VELCADE® (bortezomib)	Front line mantle cell lymphoma	US					
MLN9708 (ixazomib)	Maintenance therapy in patients with multiple myeloma following autologous stem cell transplant	US/EU			●		
NESINA® (alogliptin)	Type 2 diabetes (fixed-dose combination with metformin)	JP			●		
MLN0264	Advanced gastrointestinal malignancies	US/EU					
ENTYVIO™ (vedolizumab)	Subcutaneous formulation	-					
TAK-058	Schizophrenia, especially CIAS*	-					
TAK-935	Diseases related to glutamate excitotoxicity	-					

*Cognitive Impairment Associated with Schizophrenia

VELCADE Demonstrated Efficacy in Patients with Previously Untreated Mantle Cell Lymphoma

Presented at 2014 American Society of Clinical Oncology (ASCO) Annual Meeting

Ph-3 study evaluating the efficacy of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma patients

- Median PFS by Independent Radiology Review Committee: 24.7 vs 14.4 months with VR-CAP vs R-CHOP (HR: 0.63; P<0.001)
- Median PFS by investigator: 30.7 vs 16.1 months with VR-CAP vs R-CHOP (HR: 0.58; P<0.001)



	R-CHOP	VR-CAP
Events, n	165	133
Median PFS, months	14.4	24.7
(95% CI)	(12.0, 16.9)	(19.8, 31.8)
HR (95% CI)	0.63 (0.50, 0.79)	
P-value	<0.001	

BRINTELLIX Demonstrated Benefits in Cognitive Function in Adult Patients with Major Depressive Disorder (MDD)

International College of Neuropsychopharmacology (CINP) World Congress

- At week 8, the mean change in the DSST – Number of Correct Symbols was statistically significantly greater for vortioxetine compared to placebo. Duloxetine was not significantly different from placebo.
- Vortioxetine demonstrated a statistically significant improvement in UPSA composite score compared to placebo at week 8, with an LS mean difference from placebo of 2.94 points.
- Vortioxetine was statistically significantly better than placebo in reducing the MADRS total score at week 8. Treatment with duloxetine also yielded statistically significant efficacy results compared to placebo, validating the clinical study.
- Path analysis indicated vortioxetine's beneficial impact on cognitive functioning in patients with MDD was a direct treatment effect rather than due to alleviation of mood and depressive symptoms.

DSST: Digit Symbol Substitution Test
UPSA: UCSD Performance-Based Skills Assessment
MADRS: Montgomery–Åsberg Depression Rating Scale

Brintellix® vortioxetine

Mahableshwarkar AR, Keefe RS, Zajecka J, Jacobson W, Chen Y, Efficacy of vortioxetine on cognitive dysfunction in adult patients with major depressive disorder: results of a randomized, double-blind, active-referenced, placebo-controlled trial. Int J Neuropsychopharmacol 2014;17(suppl S1) Abstract LP-02-016

BRINTELLIX Demonstrated Favorable Sexual Dysfunction Profile Compared to Escitalopram in Patients with MDD

American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

- Vortioxetine was statistically significantly superior to escitalopram in improving SSRI-induced treatment emergent sexual dysfunction in patients with well treated MDD as measured by change in CSFQ-14 total score at week 8.
- Evaluation of CSFQ-14 sub-scales demonstrated a greater clinical benefit overall, reaching statistically significant clinical response in favor of vortioxetine on 4 of the 5 dimensions (pleasure, desire/frequency, desire/interest, arousal/erection, orgasm) and all 3 phases (desire, arousal, orgasm) of sexual functioning after 8 weeks of treatment.

Change from Baseline in CSFQ-14 Total Score by Visit (MMRM, LS Means)



- Positive values indicate improvement in sexual function. *P<0.05, **P<0.01
- CSFQ-14: Changes in Sexual Functioning Questionnaire Short-Form

Strategic Alliance with MacroGenics, Inc.

About this Alliance

- Option agreement for the exclusive worldwide development and commercialization of MGD010 following completion of Ph-1 study

What is MGD010?

- Product candidate that incorporates MacroGenics' proprietary platform for Dual-Affinity Re-Targeting (DART®) to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins.
- Currently in pre-clinical development for the treatment of autoimmune diseases

What is the DART® Platform?

- Dual-Affinity Re-Targeting (DART®) platform enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure

Ensuring Steady Pipeline Approval



Forward-Looking Statements

This presentation contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future.

All forward-looking statements are based on judgments derived from the information available to the Company at this time. Forward looking statements can sometimes be identified by the use of forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "continue," "seek," "pro forma," "potential," "target, " "forecast," or "intend" or other similar words or expressions of the negative thereof.

Certain risks and uncertainties could cause the Company's actual results to differ materially from any forward looking statements contained in this presentation. These risks and uncertainties include, but are not limited to, (1) the economic circumstances surrounding the Company's business, including general economic conditions in the US and worldwide; (2) competitive pressures; (3) applicable laws and regulations; (4) the success or failure of product development programs; (5) decisions of regulatory authorities and the timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding the safety or efficacy of marketed products or product candidates; and (8) integration activities with acquired companies.

We assume no obligation to update or revise any forward-looking statements or other information contained in this presentation, whether as a result of new information, future events, or otherwise.